Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $11.00 price target on the stock, up previously from $3.00.
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) [Yahoo! Finance]
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results